NNRX Nutranomics Enters into LOI to Acquire GenEpic™ Prostate Cancer Treatment
DRAPER, Utah, Nov. 1, 2013 /PRNewswire/ -- Nutranomics, Inc. (OTCBB: NNRX) (OTCQB: NNRX) ("Nutranomics" or the "Company") is pleased to report that it has entered into a non-binding Letter of Intent with Genesar Nutraceuticals, LLC ("Genesar"), with the intent of completing a licencing agreement to market and distribute GenEpic™, a Genesar developed product that is currently undergoing FDA approved human clinical studies.
"GenEpic™ is an exciting and very promising natural treatment for prostate cancer that does not consist of chemotherapy or radiation, but rather focuses on adenosine-triphosphate (ATP) inhibition in cells," explained Nutranomics' CEO Dr. Tracy K. Gibbs. "For the past few weeks, we have been discussing the potential acquisition of the exclusive distribution rights to GenEpic™ and we are pleased that Genesar now wants to move forward to put together a formal licencing agreement."
GenEpic™ is a natural therapeutic formula containing 70 vitamins and minerals, 32 herbs, and 16 enzymes and phytonutrients, which are intended to help restore essential nutrients lost due to stress, aging, and disease. GenEpic™ has been formulated by a respected team of five scientists and natural medicine experts, including Dr. Gibbs, to enhance bones/muscles, brain/memory, heart/circulatory function, mood, eyesight, metabolism, immune system, anti-oxidants, hormone support and digestive systems. Case studies and previous clinical trials have shown that the GenEpic™ formula can have a positive effect in fighting disease. GenEpic™ is currently the subject of an FDA approved human clinical study on prostate cancer treatment and recovery that is expected to be completed within the next 30 days.
The potential completion of a GenEpic™ distribution licence is subject to the parties entering into a definitive agreement. There can be no assurance that any transaction will be completed as proposed or at all.
About Nutranomics
Nutranomics is a publicly traded company engaged in research and development of nutritional food products. In 1997, Nutranomics produced and branded its own product line, and began to sell to the retail outlets and to the public. Nutranomics has also produced formulas for hundreds of other companies. Nutranomics' mission is to increase human health and longevity through education and self-awareness. The Company has sales representatives throughout North America and Asia.
For further information regarding Nutranomics, Inc., please contact our investor relations representatives at ir@nutranomics.com or call toll-free (888) 616-3999.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements." Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include the Company's intent to acquire a GenEpic™ distribution licence and the completion of FDA approved human clinical trials. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products and operating as a development stage company, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by applicable law, including the securities laws of the United States. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
SOURCE Nutranomics, Inc.
Copyright 2013 PR Newswire
DRAPER, Utah, Nov. 1, 2013 /PRNewswire/ -- Nutranomics, Inc. (OTCBB: NNRX) (OTCQB: NNRX) ("Nutranomics" or the "Company") is pleased to report that it has entered into a non-binding Letter of Intent with Genesar Nutraceuticals, LLC ("Genesar"), with the intent of completing a licencing agreement to market and distribute GenEpic™, a Genesar developed product that is currently undergoing FDA approved human clinical studies.
"GenEpic™ is an exciting and very promising natural treatment for prostate cancer that does not consist of chemotherapy or radiation, but rather focuses on adenosine-triphosphate (ATP) inhibition in cells," explained Nutranomics' CEO Dr. Tracy K. Gibbs. "For the past few weeks, we have been discussing the potential acquisition of the exclusive distribution rights to GenEpic™ and we are pleased that Genesar now wants to move forward to put together a formal licencing agreement."
GenEpic™ is a natural therapeutic formula containing 70 vitamins and minerals, 32 herbs, and 16 enzymes and phytonutrients, which are intended to help restore essential nutrients lost due to stress, aging, and disease. GenEpic™ has been formulated by a respected team of five scientists and natural medicine experts, including Dr. Gibbs, to enhance bones/muscles, brain/memory, heart/circulatory function, mood, eyesight, metabolism, immune system, anti-oxidants, hormone support and digestive systems. Case studies and previous clinical trials have shown that the GenEpic™ formula can have a positive effect in fighting disease. GenEpic™ is currently the subject of an FDA approved human clinical study on prostate cancer treatment and recovery that is expected to be completed within the next 30 days.
The potential completion of a GenEpic™ distribution licence is subject to the parties entering into a definitive agreement. There can be no assurance that any transaction will be completed as proposed or at all.
About Nutranomics
Nutranomics is a publicly traded company engaged in research and development of nutritional food products. In 1997, Nutranomics produced and branded its own product line, and began to sell to the retail outlets and to the public. Nutranomics has also produced formulas for hundreds of other companies. Nutranomics' mission is to increase human health and longevity through education and self-awareness. The Company has sales representatives throughout North America and Asia.
For further information regarding Nutranomics, Inc., please contact our investor relations representatives at ir@nutranomics.com or call toll-free (888) 616-3999.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements." Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include the Company's intent to acquire a GenEpic™ distribution licence and the completion of FDA approved human clinical trials. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products and operating as a development stage company, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by applicable law, including the securities laws of the United States. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
SOURCE Nutranomics, Inc.
Copyright 2013 PR Newswire
